AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways

Reproductive Sciences

Volumn 18, Issue 9, 2011, Pages 832-841

  Mendivil, Albert ^a   Zhou, Chunxiao ^b   Cantrell, Leigh A ^c   Gehrig, Paola A ^b   Malloy, Kim M ^b   Blok, Leen J ^d   Burger, Curt W ^d   Bae Jump, Victoria L ^b  

^a Gynecologic Oncology Associates   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

endometrial cancer; insulin growth factor 1; insulin growth factor 1 receptor; mitogen activated protein kinase pathway; phosphatidylinositol 3 kinase Akt pathway; telomerase

Indexed keywords

GANITUMAB; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; TELOMERASE;

EID: 80051989903     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719111398501     Document Type: Article

References (22)

1. Chia VM, Newcomb PA, Trentham-Dietz A, Hampton JM. Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer. 2007 ; 17 (2). 441-446 (Pubitemid 46426761)
2. Cust AE, Kaaks R, Friedenreich C, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab. 2007 ; 92 (1). 255-263 (Pubitemid 46067541)
3. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007 ; 16 (2). 276-280 (Pubitemid 46383346)
4. Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006 ; 106 (11). 2376-2381 (Pubitemid 43787661)
5. McCampbell AS, Broaddus RR, Loose DS, Davies PJ. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006 ; 12 (21). 6373-6378 (Pubitemid 44799707)
6. Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-i as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008 ; 17 (4). 921-929 (Pubitemid 351536424)
7. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets. 2008 ; 12 (5). 589-603 (Pubitemid 351699478)
8. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008 ; 14 (20). 6364-6370
9. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov. 2009 ; 4 (1). 54-72
10. Rodon J, DeSantos V, Ferry RJ, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther. 2008 ; 7 (9). 2575-2588
11. Hernandez-Sanchez C, Blakesley V, Kalebic T, Helman L, LeRoith D. The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis. J Biol Chem. 1995 ; 270 (49). 29176-29181
12. Lopaczynski W, Terry C, Nissley P. Autophosphorylation of the insulin-like growth factor I receptor cytoplasmic domain. Biochem Biophys Res Commun. 2000 ; 279 (3). 955-960 (Pubitemid 32042883)
13. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 1999 ; 253 (1). 1-6
14. Beltran PJ, Mitchell P, Chung YA, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther. 2009; 8(5):1095-1105. :
15. Hanifi-Moghaddam P, Sijmons B, Ott MC, et al. The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen-and progesterone-responsive endometrial cancer cell line. J Mol Endocrinol. 2006 ; 37 (3). 405-413 (Pubitemid 46085166)
16. Bièche I, Nogues C, Paradis V, et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000 ; 6 (2). 452-459 (Pubitemid 30111463)
17. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009 ; 27 (34). 5800-5807
18. Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. 2005 ; 11 (8). 3065-3074 (Pubitemid 40525213)
19. Wetterau LA, Francis MJ, Ma L, Cohen P. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J Clin Endocrinol Metab. 2003 ; 88 (7). 3354-9 (Pubitemid 36877516)
20. Pavelić J, Radaković B, Pavelić K. Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol. 2007 ; 105 (3). 727-735 (Pubitemid 46734203)
21. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 2005 ; 113 (2). 316-328 (Pubitemid 39628325)
22. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003 ; 63 (16). 5073-5083 (Pubitemid 37022647)